Expert panel on prostate cancer screening and prevention

Apr 26 2009

The American Urological Association (AUA) will offer journalists the opportunity to hear from world-renowned experts about prostate cancer screening and prevention during a special expert panel session on April 27, 2009 at 12:15 p.m.

Authors representing the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, the European Randomised Study of Screening for Prostate Cancer (ERSPC) and the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial will present data to the media. The panel will be moderated by William J. Catalona, MD.

The event will be immediately followed by a special press conference during which the AUA will unveil to the media its new Best Practice Statement on Prostate-Specific Antigen (PSA) testing. This guidance updates the AUA's previous statement, which was issued in 2000, and will provide valuable guidance about which patients should be offered the PSA test as well as when a biopsy is indicated following an elevated PSA reading.

The following experts are participating in the panel:

Gerald L. Andriole, MD- Headline Results of the REDUCE Trial: The Effect of Dutasteride on Prostate Cancer Risk Reduction. (Abstract LB1)

E. David Crawford, MD- Potential for increase in screening interval based on initial PSA: Data from the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. (Abstract 2123)

Hans Lilja, MD- Prostate-specific antigen level at age 60 and death from prostate cancer. (Abstract 162)

Judd W. Moul, MD- Say ‘No' to the US Preventive Task Force recommendations to no longer offer prostate cancer screening after age 75? (Abstract 2200)

Fritz H. Schröder, MD- Screening and Prostate-Cancer Mortality in a Randomized European Study.
(N Engl J Med 2009, 360:1320-1328)

Reporters interested in covering this event should contact AUA Communications Manager Wendy Waldsachs Isett at 410... or [email protected] for additional information about the session.